Clinical trial · Observational
Change in Body Weight During Treatment of Advanced Colorectal Cancer
Clinical Significance of Change in Body Weight During Treatment of Advanced Colorectal Cancer Patients - A Pilot Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Colorectal cancer (CRC) is a significant and growing health burden in Hong Kong. According to data from Hong Kong Cancer Registry, CRC ranked the first in incidence and the second in mortality, with around 5,000 new cases diagnosed and more than 2,000 cancer-related mortality in 2014. The investigators aim to evaluate the association between serial weight change during first line treatment and outcomes in patients with metastatic CRC.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer, Colorectal | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
| Chemotherapy Effect | — | UNRESOLVED | — |
| Prognosis | — | UNRESOLVED | — |
| Weight Loss | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| first line systemic treatment for colorectal cancer | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- stage IV colorectal cancer
- description
- stage IV colorectal cancer on first line systemic treatment are observed for the trend of weight change and treatment outcomes
- interventionNames
- Drug: first line systemic treatment for colorectal cancer
Primary outcomes (2)
- measure
- Progression-free survival
- timeFrame
- From date of start of anti-cancer treatment until the date of first documented progression (assessed by physical examination, imaging, or blood biomarkers) or date of death from any cause, whichever came first, assessed up to 60 months
- description
- Survival time from start of anti-cancer treatment until disease progression, or death from disease, or loss of follow-up
- measure
- Overall survival
- timeFrame
- From date of start of anti-cancer treatment until the date of death from any cause (assessed by physical examination, imaging, or blood biomarkers), assessed up to 60 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically proven adenocarcinoma of colorectal origin * Stage IV disease with systemic treatment * Estimated life expectancy \>3 months * Adequate organ functions Exclusion Criteria: * Eastern Cooperative Oncology Group performance status 3 or above * Pregnancy * Human immunodeficiency virus infection and acquired immune deficiency syndrome (HIV/AIDS) * Past medical history of another cancer
References
Publications (0)
Data not yet available